Cantor Fitzgerald Estimates TSE:ONC FY2024 Earnings

Oncolytics Biotech Inc. (TSE:ONC) – Equities research analysts at Cantor Fitzgerald decreased their FY2024 EPS estimates for shares of Oncolytics Biotech in a research note issued on Wednesday, November 13th. Cantor Fitzgerald analyst L. Chen now anticipates that the company will earn ($0.42) per share for the year, down from their previous forecast of ($0.36). The consensus estimate for Oncolytics Biotech’s current full-year earnings is ($0.41) per share.

Separately, Raymond James raised shares of Oncolytics Biotech to a “moderate buy” rating in a research note on Thursday, November 14th.

Oncolytics Biotech Price Performance

Shares of ONC opened at C$1.39 on Monday. Oncolytics Biotech has a fifty-two week low of C$1.15 and a fifty-two week high of C$2.32. The firm’s 50 day moving average price is C$1.50 and its 200 day moving average price is C$1.45. The company has a market cap of C$106.84 million, a P/E ratio of -3.63 and a beta of 1.35. The company has a quick ratio of 8.86, a current ratio of 4.99 and a debt-to-equity ratio of 6.09.

About Oncolytics Biotech

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.